182 related articles for article (PubMed ID: 27443511)
21. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
22. The myelodysplastic syndromes. Part I. What are they? Part II. Classification.
Galton DA
Scand J Haematol Suppl; 1986; 45():11-20. PubMed ID: 3515515
[No Abstract] [Full Text] [Related]
23. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
24. [Evolution to megakaryoblastic leukemia observed in myelodysplastic syndrome with erythrolekemia-like features].
Takai K; Sanada M; Shibuya H
Rinsho Ketsueki; 1992 Aug; 33(8):1071-6. PubMed ID: 1404864
[TBL] [Abstract][Full Text] [Related]
25. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
26. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
27. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
Wang SA; Tang G; Fadare O; Hao S; Raza A; Woda BA; Hasserjian RP
Mod Pathol; 2008 Nov; 21(11):1394-402. PubMed ID: 18839018
[TBL] [Abstract][Full Text] [Related]
28. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
[TBL] [Abstract][Full Text] [Related]
29. Pure erythroid leukemia.
Wang W; Wang SA; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Mar; 92(3):292-296. PubMed ID: 28006859
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
Pourabdollah M; Chang H
Blood; 2017 Feb; 129(7):918. PubMed ID: 28209754
[No Abstract] [Full Text] [Related]
31. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
33. The natural history of trilinear myelodysplastic syndrome and erythroleukemia.
Michiels JJ; van der Meulen J; Brederoo P
Haematologica; 1997; 82(4):452-54. PubMed ID: 9299860
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
35. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.
Liu W; Hasserjian RP; Hu Y; Zhang L; Miranda RN; Medeiros LJ; Wang SA
Mod Pathol; 2011 Mar; 24(3):375-83. PubMed ID: 21102413
[TBL] [Abstract][Full Text] [Related]
36. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification.
Park S; Picard F; Azgui Z; Viguie F; Merlat A; Guesnu M; Leblond V; Dreyfus F
Leuk Res; 2002 May; 26(5):423-9. PubMed ID: 11916513
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
38. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
39. Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia.
Ryu S; Park HS; Kim SM; Im K; Kim JA; Hwang SM; Yoon SS; Lee DS
Leuk Res; 2018 Jul; 70():13-19. PubMed ID: 29729583
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes in childhood: description of seven cases.
Vitale A; Testi AM; Moleti ML; Vignetti M; Arcese W; Fenu S; Cedrone M; De Felice L; Amadori S; Mandelli F
Ann Hematol; 1994 May; 68(5):241-5. PubMed ID: 8018765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
